Several lines of evidence indicate that the dysregulation of RUNX2 expression is frequently detectable in a variety of human cancers and its higher expression level is tightly correlated with poor clinical outcome of the patients [24,25,26]. This evidence concerns the gene RUNX2 and cancer.